These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 34551784)

  • 21. Altered Plasma Clot Properties and Trauma-Related Venous Thromboembolism despite Thromboprophylaxis.
    Goldman S; Frączek P; Szklanny K; Papuga-Szela E; Stanisz A; Undas A
    Thromb Haemost; 2018 Apr; 118(4):654-663. PubMed ID: 29618152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microfluidic Modeling of Thrombolysis.
    Loyau S; Ho-Tin-Noé B; Bourrienne MC; Boulaftali Y; Jandrot-Perrus M
    Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2626-2637. PubMed ID: 30354249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diabetes and atherothrombosis: The circadian rhythm and role of melatonin in vascular protection.
    Otamas A; Grant PJ; Ajjan RA
    Diab Vasc Dis Res; 2020; 17(3):1479164120920582. PubMed ID: 32506946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Importance of the structure of the clot in thrombolysis].
    Soria C; Soria J; Mirshahi M; Desvignes P; Bonnet P; Caen JP
    Ann Biol Clin (Paris); 1987; 45(2):207-11. PubMed ID: 2441630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coagulation and fibrinolysis in diabetes.
    Alzahrani SH; Ajjan RA
    Diab Vasc Dis Res; 2010 Oct; 7(4):260-73. PubMed ID: 20847109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of 17 beta-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitus.
    Brussaard HE; Leuven JA; Krans HM; Kluft C
    Vascul Pharmacol; 2002 Aug; 39(3):141-7. PubMed ID: 12616982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased Plasma Fibrinolytic Potential As a Risk for Venous and Arterial Thrombosis.
    Lisman T
    Semin Thromb Hemost; 2017 Mar; 43(2):178-184. PubMed ID: 27472427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetes mellitus as a prothrombotic condition.
    Grant PJ
    J Intern Med; 2007 Aug; 262(2):157-72. PubMed ID: 17645584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity.
    Ajjan RA; Gamlen T; Standeven KF; Mughal S; Hess K; Smith KA; Dunn EJ; Anwar MM; Rabbani N; Thornalley PJ; Philippou H; Grant PJ
    Blood; 2013 Jul; 122(1):134-42. PubMed ID: 23699598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spontaneous reperfusion in STEMI: Its mechanisms and possible modulation.
    Leader JH; Kanji R; Gorog DA
    Kardiol Pol; 2024; 82(4):363-374. PubMed ID: 38493469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged Prothrombotic Effects of Antecedent Hypoglycemia in Individuals With Type 2 Diabetes.
    Chow E; Iqbal A; Walkinshaw E; Phoenix F; Macdonald IA; Storey RF; Ajjan R; Heller SR
    Diabetes Care; 2018 Dec; 41(12):2625-2633. PubMed ID: 30327358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombosis in diabetes: a shear flow effect?
    Westein E; Hoefer T; Calkin AC
    Clin Sci (Lond); 2017 Jun; 131(12):1245-1260. PubMed ID: 28592700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus.
    García Frade LJ; de la Calle H; Torrado MC; Lara JI; Cuellar L; García Avello A
    Thromb Res; 1990 Jul; 59(1):51-9. PubMed ID: 2119076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sex-specific alteration to α2-antiplasmin incorporation in patients with type 2 diabetes.
    Bryk AH; Siudut J; Broniatowska E; Bagoly Z; Baráth B; Katona É; Undas A
    Thromb Res; 2020 Jan; 185():55-62. PubMed ID: 31770688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antithrombotic medications and their impact on fibrin clot structure and function.
    Undas A; Zabczyk M
    J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30415236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
    Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
    Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers.
    Alzahrani SH; Hess K; Price JF; Strachan M; Baxter PD; Cubbon R; Phoenix F; Gamlen T; Ariëns RA; Grant PJ; Ajjan RA
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2282-7. PubMed ID: 22996148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered fibrin clot properties and fibrinolysis in patients with atrial fibrillation: practical implications.
    Undas A
    Europace; 2020 Feb; 22(2):185-194. PubMed ID: 31625555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extracellular Histones Inhibit Fibrinolysis through Noncovalent and Covalent Interactions with Fibrin.
    Locke M; Longstaff C
    Thromb Haemost; 2021 Apr; 121(4):464-476. PubMed ID: 33131044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interplay between elevated cellular fibronectin and plasma fibrin clot properties in type 2 diabetes.
    Konieczyńska M; Bryk AH; Malinowski KP; Draga K; Undas A
    Thromb Haemost; 2017 Aug; 117(9):1671-1678. PubMed ID: 28569923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.